Leading DNA vaccine discovery company, Inovio Biomedical Corporation announced that their Scientific Advisory Board Chairman, Dr. David B. Weiner, highlighted advances in the company’s leading electroporation-delivered SynCon™ DNA vaccines at the AIDS Vaccine 2009 Conference in Paris.

The study, led by Dr. Weiner’s team at the University of Pennsylvania, included collaborators from Inovio and Merck. The team previously reported that DNA vaccines delivered using electroporation induced dramatic increases in T-cell and antibody-based immune responses. This collaborative study was the first to directly compare a DNA plasmid-electroporation platform with a recombinant Ad5 vector in an SIV model in non-human primates.

Dr. Weiner presented pre-clinical data showing higher levels of immune responses induced by Inovio’s DNA vaccines than to those induced by the recombinant adenovirus serotype 5 (Ad5) vector. Historically, recombinant Ad5 vector has been shown to be one of the most potent viral vectors for vaccines.

In his presentation, Dr. Weiner also

...

Applied DNA Sciences Inc.’s stock is currently trading at $0.17, up 21.43%. The number of shares traded so far is in excess of 17.3 million shares, well above the average volume of about 2.8 million shares. August 4, 2009, the company’s stock was highlighted in the QualityStocks Daily Newsletter when the stock was trading at $0.137. Applied DNA Sciences is up nearly 25% since the mention, a nice move in such a short time.

The company, a provider of DNA-based security solutions, has made a couple of important announcements recently. First, Applied DNA Sciences reported that its anti-counterfeit technologies can be deployed in covert programs that seek to identify “leaks” in supply chains. The company also announced that it can create botanical SigNature DNA markers that individually mark valuables and collectibles that require a forensic level of security and authentication.

Interested in investing into exciting small cap companies like Applied DNA Sciences?

...

Leading provider of DNA-based security solutions, Applied DNA Sciences, Inc., announced today that it has joined forces with Banknote Watch, government and police companies devoted to fighting the ongoing battle against cash-in-transit (CIT) crimes. The company’s SigNature® DNA marks, which work to dissuade criminals, helps the CIT companies lower costs and minimize risk to their personnel. The UK police have responded positively to the forensic quality of the evidence produced by SigNature DNA.

APDN has increased its market share of the taggants used by the UK CIT industry by almost 20%. The company hopes to continue increasing market penetration and revenue by broadening its authentication client base. Based on its recent successful authentications of recovered cash from CIT crimes, APDN expects that the value of its DNA evidence will add to its proliferation in prosecuting criminals. The next steps in APDN’s growth strategy are to ensure that all cash degradation systems,

...

Orchid Cellmark Inc. (ORCH) is a leading provider of DNA testing services for forensic, human identity and agricultural applications in the U.S. and the U.K.Through its facility in the U.K., Orchid conducted genotyping services under the U.K. government's project to help British farmers breed sheep with reduced susceptibility to the animal disease scrapie. The company expanded its reach in the U.S. with the acquisition of ReliaGene in October 2007.The company is now leveraging its expertise in DNA testing to enter into new markets like pork traceability, immigration testing and security applications. The company has won a major part of the mega tender in the U.K., which will result in annual revenues of $10 million for the next 3 years.We believe it is the right time to accumulate Orchid stock as we anticipate significant appreciation in the stock price in the near future. ...